Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ascendis Pharma ( (ASND) ) has shared an update.
On June 9, 2025, Ascendis Pharma released interim topline data from its Phase 2 COACH Trial, evaluating the combination of TransCon CNP and TransCon hGH in children with achondroplasia. The results showed promising improvements in growth velocity and body proportionality, with the combination treatment being well-tolerated. This development could significantly enhance the company’s position in the growth disorders market and offer new treatment paradigms for achondroplasia.
The most recent analyst rating on (ASND) stock is a Buy with a $165.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
Ascendis Pharma’s stock reflects a mix of strong revenue growth and innovative product development, offset by significant operational losses and financial instability. The technical analysis shows strong momentum, but valuation remains challenging with negative earnings. The earnings call further underscores the duality of growth potential and financial constraints.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies for rare diseases. The company’s primary products include TransCon CNP and TransCon hGH, which are designed to address growth disorders such as achondroplasia.
Average Trading Volume: 509,288
Technical Sentiment Signal: Buy
Current Market Cap: $10.45B
See more insights into ASND stock on TipRanks’ Stock Analysis page.